Evidence map›Paper›PMID 31365340›Full record

ArticleEuropean journal of rheumatology2019

Serum hepcidin level and rheumatoid arthritis disease activity.

Maryam Sahebari, Zahra Rezaieyazdi, Seyed Isaac Hashemy, Sahar Khorasani, Sanaz Shahgordi, Mohammad Karim Alizadeh, Abdolmomen Ghaeni, Mandana Khodashahi

Open access · diamondAbstract read
In one paragraph

Article in European journal of rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Maryam SahebariRheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID http://orcid.org/0000-0003-3609-9041
Zahra RezaieyazdiRheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID http://orcid.org/0000-0002-4773-7910
Seyed Isaac HashemySurgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID http://orcid.org/0000-0002-1323-5250
Sahar KhorasaniStudent Research Committee, Mashhad University of Medical Sciences School of Medicine, Mashhad, Iran.ORCID http://orcid.org/0000-0001-8900-8399
Sanaz ShahgordiStudent Research Committee, Mashhad University of Medical Sciences School of Medicine, Mashhad, Iran.ORCID http://orcid.org/0000-0002-6047-4932
Mohammad Karim AlizadehStudent Research Committee, Mashhad University of Medical Sciences School of Medicine, Mashhad, Iran.ORCID http://orcid.org/0000-0001-8197-5448
Abdolmomen GhaeniStudent Research Committee, Mashhad University of Medical Sciences School of Medicine, Mashhad, Iran.ORCID http://orcid.org/0000-0001-5715-7066
Mandana KhodashahiRheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID http://orcid.org/0000-0003-1198-1783
Mashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe present study aimed to determine the relationship between the serum hepcidin level and disease activity in patients with rheumatoid arthritis (RA).

methodsThis study was conducted on 80 patients with RA (36 cases with anemia of chronic disease [ACD] and 44 patients without ACD). Disease activity was measured by the 28-joint Disease Activity Score based on the erythrocyte sedimentation rate (DAS28-ESR). According to the DAS28-ESR score, 52 and 28 cases were categorized as inactive to moderately active RA (DAS28-ESR≤5.1) and highly active RA (DAS28-ESR>5.1), respectively. In addition, the serum hepcidin level was evaluated in all patients to determine its correlation with the DAS28-ESR score.

resultsThere was no significant difference between the RA with ACD and RA without ACD groups in terms of the median (interquartile range) hepcidin level (1207 [985.2] vs. 923.8 [677.3] ng/mL; P=0.57). Likewise, no significant difference was observed between the active RA and inactive to moderately active RA groups in this regard (1131.8 [991.3] vs. 1090.9 [631.4] ng/mL; P=0.53).

conclusionHepcidin has no association with disease activity in RA. Therefore, it is not necessary to measure hepcidin to determine the RA activity.

Identifiers

PMID31365340
PMCPMC6467328
OpenAlexW2905850274

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.